Chemed Corporation reported solid performance for both VITAS and Roto-Rooter in Q3 2021. VITAS, a hospice provider, faced challenges in staffing licensed professionals and increasing salaries, but the company expects reimbursement rate increases to offset these cost pressures. Senior housing occupancy disruptions continued to impact hospice referrals, but there are signs of improvement. Roto-Rooter expanded its technician manpower by 8%, with average compensation exceeding $81,000 annually. Chemed repurchased 350,000 shares, bringing total share repurchases since 2007 to approximately 15.2 million shares at an average cost of $113.04 per share. The company raised its full-year 2021 guidance, expecting adjusted earnings per share of $19.00 to $19.20, excluding certain items. VITAS revenue before the Medicare Cap is estimated to decline 5%, with an adjusted EBITDA margin of 18.8%. Roto-Rooter's revenue is forecasted to grow 17.3%, with an adjusted EBITDA margin between 28.5% and 29%.